The results are not permanent without maintenance sessions and lifestyle support
Resources from Diabetes UK and the NHS can help patients understand food labelling and make appropriate choices
Read it on Drug Hunter: drughunters.com/4tP9Jut Orforglipron: The First Approved Oral Non-Peptide GLP-1R Agonist for Obesity | drughunters.com/4tP9Jut Orforglipron is now FDA approved for obesity, marking a major milestone for orally available small molecule GLP-1 therapies
Acta Diabetol 9:12 Bartel S et al (2024) Use of glucagon-like peptide-1 receptor agonists in eating disorder populations
Many patients on tirzepatide are now achieving 20% or more total body weight loss, a result that, until very recently, you could only realistically expect from procedures like gastric sleeve surgery
MYSM1 is a histone deubiquitination-mediating transcriptional regulator and its deficiency alters gene expression of iron metabolism-regulating proteins, which promotes iron accumulation, and downregulates expression of the protective GPX4 gene [174]
